- Ivax Pharmaceuticals of the USA says it has long-term strategic plans for Galena, a pharmaceuticals producer in Opava in the Czech Republic, in which it has a 67% stake. The Czech company posted turnover of 1.8 billion koruna ($65.1 million) in 1995, and net profits of 50 million koruna, up 31%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze